(NASDAQ: CDTX) Cidara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.28%.
Cidara Therapeutics's earnings in 2025 is -$182,981,000.On average, 1 Wall Street analyst forecast CDTX's earnings for 2025 to be -$92,345,140, with the lowest CDTX earnings forecast at -$92,345,140, and the highest CDTX earnings forecast at -$92,345,140. On average, 1 Wall Street analyst forecast CDTX's earnings for 2026 to be -$189,878,209, with the lowest CDTX earnings forecast at -$189,878,209, and the highest CDTX earnings forecast at -$189,878,209.
In 2027, CDTX is forecast to generate -$216,077,251 in earnings, with the lowest earnings forecast at -$216,077,251 and the highest earnings forecast at -$216,077,251.